Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice

Cancer Research

Volumn 70, Issue 4, 2010, Pages 1367-1376

  Moussavi, Maryam ^a   Fazli, Ladan ^a   Tearle, Howard ^a   Guo, Yubin ^a   Cox, Michael ^a   Bell, John ^b   Ong, Christopher ^a   Jia, William ^a   Rennie, Paul S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; LUCIFERASE; ONCOLYTIC VIRUS; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; IMMUNE DEFICIENCY; INJECTION; INOCULATION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NICK END LABELING; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN; TRANSGENIC MOUSE; TUMOR XENOGRAFT; VESICULAR STOMATITIS VIRUS; VIRUS DETECTION; VIRUS REPLICATION; VIRUS STRAIN; XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA; CELL SURVIVAL; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; HUMANS; MALE; MICE; MICE, KNOCKOUT; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; VERO CELLS; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL LOAD; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76749129371     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2377     Document Type: Article

References (44)

1. American Cancer Society. Cancer facts and figures 2008. Atlanta: American Cancer Society; 2008.
2. Mazhar D, Waxman J. Early chemotherapy in prostate cancer. Nat Clin Pract Urol 2008;5:486-93.
3. Moore CM, Pendse D, Emberton M. Photodynamic therapy for prostate cancer - a review of current status and future promise. Nat Clin Pract Urol 2009;6:18-30.
4. Drake CG. Immunotherapy for metastatic prostate cancer. Urol Oncol 2008;26:438-44.
5. Moinpour CM, Hayden KA, Unger JM, et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 2008;26: 112-20.
6. Klotz L. Active surveillance for prostate cancer: trials and tribulations. World J Urol 2008;26:437-42.
7. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
8. Alajez NM, Mocanu JD, Shi W, et al. Efficacy of systemically administered mutant vesicular stomatitis virus (VSV△51) combined with radiation for nasopharyngeal carcinoma. Clin Cancer Res 2008;14: 4891-7.
9. Ribacka C, Hemminki A. Virotherapy as an approach against cancer stem cells. Curr Gene Ther 2008;8:88-96.
10. Zhang W, Cai R, Luo J, et al. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma. Cancer Biol Ther 2007;6:1726-32.
11. Nguyen TL, Abdelbary H, Arguello M, et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A 2008;105:14981-6.
12. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821-5.
13. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003;4:263-75.
14. Nagano K, Masters JR, Akpan A, et al. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene 2004;23: 1693-703.
15. Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM, Gao WQ. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci U S A 2002;99:2830-5.
16. Balachandran S, Barber GN. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 2000;50:135-8.
17. Balachandran S, Roberts PC, Brown LE, et al. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 2000;13:129-41.
18. Lichty BD, Power AT, Stojdl DF, Bell JC. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 2004;10:210-6.
19. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-37.
20. Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-21.
21. Wu X, Wu J, Huang J, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 2001;101:61-9.
22. Fraser MM, Bayazitov IT, Zakharenko SS, Baker SJ. Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities. Neuroscience 2008; 151:476-88.
23. Homma T, Fukushima T, Vaccarella S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 2006;65:846-54.
24. Breitbach CJ, Paterson JM, Lemay CG, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007;15:1686-93.
25. Hadaschik BA, Zhang K, So AI, et al. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res 2008;68:4506-10.
26. Moussavi M, Assi K, Gomez-Munoz A, Salh B. Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis 2006;27:1636-44.
27. Suzuki A, Yamaguchi MT, Ohteki T, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001; 14:523-34.
28. Oliere S, Arguello M, Mesplede T, et al. Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J Virol 2008;82:5735-49.
29. Tumilasci VF, Oliere S, Nguyen TL, Shamy A, Bell J, Hiscott J. Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol 2008;82:8487-99.
30. Margiotti K, Wafa LA, Cheng H, Novelli G, Nelson CC, Rennie PS. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells. Mol Cancer 2007;6:38.
31. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434: 772-7.
32. Hadaschik BA, Zhang K, So AI, et al. [Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer]. Urologe A 2008;47:1145-51.
33. Ireland DD, Reiss CS. Gene expression contributing to recruitment of circulating cells in response to vesicular stomatitis virus infection of the CNS. Viral Immunol 2006;19:536-45.
34. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5:965-76.
35. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001;7:781-7.
36. NelsonWG, Simons JW, Mikhak B, et al. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 2000;46 Suppl:S67-72.
37. Diaz RM, Galivo F, Kottke T, et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007;67: 2840-8.
38. Lun X, Senger DL, Alain T, et al. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(△M51)) on multifocal and invasive gliomas. J Natl Cancer Inst 2006;98:1546-57.
39. Ahmed M, Cramer SD, Lyles DS. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 2004;330:34-49.
40. Maggini J, Raiden S, Salamone G, Trevani A, Geffner J. Regulation of neutrophil apoptosis by cytokines, pathogens and environmental stressors. Front Biosci 2009;14:2372-85.
41. Stevens JG, Cook ML. Restriction of herpes simplex virus by macrophages. An analysis of the cell-virus interaction. J Exp Med 1971; 133:19-38.
42. Belardelli F, Vignaux F, Proietti E, Gresser I. Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis virus and encephalomyocarditis virus. Proc Natl Acad Sci U S A 1984;81:602-6.
43. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 2007;282: 20053-7.
44. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:9-17.